Artesunate enhances the immune response of rabies vaccine as an adjuvant |
| |
| Affiliation: | 1. College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China;2. Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA;3. Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA 71130-3932, USA;1. Beijing Children’s Hospital Affiliated to Capital Medical University, Beijing, China;2. Shenzhen Children’s Hospital, Shenzhen, China;1. Department of Bioengineering, McGill University, Montreal, Canada;2. Protein Expression Facility, The University of Queensland, Brisbane, Australia;3. Merck Research Laboratories, West Point, PA, USA;1. School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia;2. Centre for Health Economics Research and Modelling Infectious Diseases (CHERM ID), Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium;3. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), Kids Research Institute, Children’s Hospital at Westmead, NSW, Australia |
| |
| Abstract: | ![]()
Rabies is an ancient zoonosis that continues to be an important health problem worldwide. Vaccination with rabies vaccine is the most important strategy to prevent rabies. Adjuvants contribute to the immune response of viral vaccine. The aim of this study was to investigate whether artemisinin derivatives artesunate and dihydroartemisinin could enhance the immunogenicity of inactivated rabies virus in mice. Administration of artesunate or dihydroartemisinin by intramuscular injection at a dose of 5 mg/kg did not cause body weight loss and unusual symptoms in mice. Mice were immunized with inactivated CVS-11 or inactivated rHEP-dG together with either artesunate or dihydroartemisinin through intramuscular injection. Blood samples were collected to investigate the virus-neutralizing antibody (VNA) titers, and challenge assays were then conducted. The results showed that the rabies VNA titers in mice co-treated with artesunate rather than dihydroartemisinin were significantly higher than in the control animals treated with the phosphate buffered saline (PBS). In addition, mice co-treated with artesunate survived from lethal rabies virus challenge compared with those treated with PBS. In contrast, co-treatment with dihydroartemisinin did not improve the survival rate of the challenged mice. The findings indicate that artesunate could be used as a new candidate adjuvant for rabies vaccination. |
| |
| Keywords: | Rabies Vaccine Adjuvant Artesunate Dihydroartemisinin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
